Nitric oxide is a potent vasodilator, making it ideal for the treatment of hypertension. iNO is FDA approved for treatment of neonates with pulmonary hypertension. Studies have shown that the administration of iNO during lung transplantation can prevent primary graft failure (PGF), improve oxygenation, and reduce pulmonary hypertension. Due to its antiseptic properties, iNO has been proposed as a treatment for chronic airway infections, especially in diseases like CF, sinusitis, tuberculosis, and COPD where airway infections are common. When added to the sweep gas
during open heart surgery and other extracorporeal circulation [ECC] applications, it has been shown to prevent both thrombosis and systemic inflammatory response syndrome by preventing platelet and white blood cell activation. iNO is a promising candidate for treatment across a variety of applications.